Renal Outcomes in People With HIV-1 and Renal Impairment Treated With B/F/TAF: Integrated Analysis from Nine Phase 3/3b Clinical Trials

Key Points

• To assess renal outcomes in people with HIV-1 and renal impairment treated with B/F/TAF.
• Integrated analysis of data from nine Phase 3/3b clinical trials
• Inclusion of 1069 individuals with mild to moderate renal impairment
• Follow-up duration of up to 240 weeks
• Renal function remained stable during the follow-up period
• Infrequent renal adverse events were reported
• Discontinuation due to renal toxicity was rare

Abstract